Weight loss medication is typically suitable for adults with a Body Mass Index (BMI) of 30 kg/m² or above, or 27 kg/m² or above if they have weight-related health conditions. Examples of qualifying weight-related health conditions may include high blood pressure, type 2 diabetes, pre-diabetes, high cholesterol, obstructive sleep apnoea, cardiovascular disease, or other obesity-related medical conditions. Eligibility is confirmed through a clinical assessment.

There is no single “best” weight loss medication for everyone. The most appropriate treatment depends on factors such as your BMI, medical history, previous weight loss attempts, lifestyle, and treatment goals. Our clinicians will help identify the most suitable option for you.

Mounjaro (tirzepatide) is a once-weekly weight loss injection that helps reduce appetite, increase feelings of fullness, and support calorie reduction. It belongs to a newer generation of weight loss medications and may be suitable for eligible patients seeking medical weight management. In clinical studies, people using Mounjaro alongside diet and lifestyle changes achieved average weight loss of up to 20% of their starting body weight over approximately 72 weeks, although individual results vary and not everyone will achieve the same outcome.

Wegovy (semaglutide) is a weekly weight loss injection that works by mimicking a natural hormone involved in appetite regulation. It helps people feel fuller for longer and can support sustainable weight loss when combined with healthy lifestyle changes. In clinical trials, people using Wegovy alongside diet and exercise lost an average of around 15% of their body weight over 68 weeks, although individual results can vary depending on factors such as starting weight, adherence to treatment, and lifestyle changes.

Both Mounjaro and Wegovy are prescription weight loss injections that help reduce appetite, increase feelings of fullness, and support weight loss when combined with healthy lifestyle changes. However, they contain different active ingredients and work in different ways within the body.
Wegovy contains semaglutide, which mimics a naturally occurring hormone called GLP-1 (glucagon-like peptide-1). This hormone helps regulate appetite by signalling to the brain that you are full, slowing stomach emptying, and reducing hunger between meals.
Mounjaro contains tirzepatide, which activates both GLP-1 and a second hormone pathway called GIP (glucose-dependent insulinotropic polypeptide). By targeting two pathways involved in appetite regulation and metabolism, Mounjaro may provide greater appetite suppression for some people and has been shown in clinical studies to support significant weight loss.
Because both medications affect the digestive system, they share many of the same potential side effects. Common side effects include nausea, vomiting, diarrhoea, constipation, indigestion, bloating, and reduced appetite. Some patients find that Mounjaro’s stronger appetite-suppressing effects can lead to more noticeable gastrointestinal side effects, particularly during dose increases, although individual experiences vary considerably. Most side effects are mild to moderate and tend to improve as the body adjusts to treatment.
Wegovy may be particularly suitable for patients who prefer a treatment with a longer track record in weight management, those who have previously responded well to GLP-1 medications, or individuals who may benefit from a more gradual approach to appetite suppression. Mounjaro may be considered for patients seeking the potential for greater weight loss or those who have not achieved their desired results with other weight loss treatments.

Orlistat is a prescription weight loss capsule that works differently from injectable treatments such as Mounjaro, Wegovy, and Saxenda. Rather than affecting appetite, Orlistat works in the digestive system by reducing the amount of fat absorbed from the food you eat. Approximately one-third of the fat consumed in a meal is prevented from being absorbed and is instead passed out of the body.
Orlistat is usually taken with meals that contain fat and is most effective when combined with a reduced-calorie, lower-fat diet and regular physical activity. Many patients find it helpful as part of a structured weight management plan, particularly if they prefer a capsule rather than an injection.
Because Orlistat affects fat absorption, eating high-fat meals while taking it can increase the likelihood of digestive side effects such as oily stools, bloating, wind, or an urgent need to use the toilet. Following a lower-fat diet can help minimise these effects and improve treatment success. During your consultation, we’ll discuss whether Orlistat is a suitable option for your weight loss goals and provide guidance on how to use it safely and effectively.

Mysimba is a prescription weight loss tablet that contains two active ingredients, naltrexone and bupropion, which work together on areas of the brain involved in appetite control and food cravings. It can help reduce hunger, improve control over eating habits, and make it easier to stick to a calorie-controlled diet. Mysimba is usually taken as a tablet and the dose is gradually increased over several weeks to help minimise side effects. It may be a suitable option for patients who prefer an oral treatment rather than weight loss injections, although suitability will depend on your medical history, current medications, and individual weight loss goals. A clinician will assess whether Mysimba is an appropriate treatment for you during your consultation.

Yes. Following a clinical assessment and confirmation of suitability, eligible patients may be prescribed weight loss medication through our online pharmacy service. We offer convenient virtual appointments with our clinicians, allowing you to discuss your treatment options and receive personalised support from the comfort of your home. Once your medication has been approved and supplied, we provide 24-hour Royal Mail delivery to ensure you receive your treatment quickly and securely. For ongoing treatment, patients can conveniently reorder their medication online, with optional follow-up consultations available whenever additional clinical support or treatment reviews are required.

Common side effects can include nausea, vomiting, diarrhoea, constipation, indigestion, and reduced appetite. These side effects occur because medications such as Mounjaro, Wegovy, and Saxenda slow stomach emptying and affect appetite-regulating hormones in the gut and brain. They are often most noticeable when starting treatment or during dose increases and usually improve as your body adjusts. Our clinical team will provide guidance on managing side effects, including advice on meal sizes, food choices, hydration, eating habits, and dose progression, helping you stay comfortable and get the most from your treatment.

Many people notice a reduction in appetite, fewer food cravings, and increased feelings of fullness within the first few weeks of starting treatment. These effects can make it easier to reduce portion sizes, avoid unnecessary snacking, and maintain healthier eating habits. Weight loss generally occurs gradually and steadily over several months, although results vary from person to person depending on factors such as starting weight, adherence to treatment, diet, physical activity levels, and individual response to the medication. For the best results, weight loss medication should be used as part of a long-term weight management plan that includes sustainable lifestyle changes and ongoing support where needed.